PureTech Health (LON:PRTC) Trading Up 14.2% - What's Next?

Key Points

• PureTech Health plc shares surged by 14.2%, reaching a last trading price of GBX 121.50 after a notable increase in trading volume by 1,053%.
• The company has a market capitalization of £293.65 million and displayed a high P/E ratio of 714.71, suggesting potentially overvalued stock given its early-stage developmental status.
• Insider transactions were reported, with Bharatt Chowrira acquiring 167,739 shares at an average price of GBX 1, indicating confidence from company insiders.

PureTech Health plc (LON:PRTC - Get Free Report)'s stock price rose 14.2% during mid-day trading on Friday . The company traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). Approximately 9,013,305 shares were traded during mid-day trading, an increase of 1,053% from the average daily volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.43).

PureTech Health Price Performance

The company has a debt-to-equity ratio of 45.82, a current ratio of 3.68 and a quick ratio of 2.51. The stock's fifty day moving average is GBX 129.46 and its 200-day moving average is GBX 129.72. The stock has a market capitalization of £303.07 million, a P/E ratio of 737.65 and a beta of 1.02.

Insider Activity at PureTech Health

In related news, insider Bharatt Chowrira acquired 167,739 shares of the business's stock in a transaction dated Thursday, July 3rd. The stock was acquired at an average price of GBX 1 per share, with a total value of £1,677.39. Corporate insiders own 13.13% of the company's stock.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.